Medtronic Q3 Earnings: Cardiovascular And Neuroscience Drive Growth, Surgical Revenue Dips, Reaffirms Annual Forecast

Core Insights - Medtronic Plc reported third-quarter 2025 sales of $8.29 billion, slightly missing the consensus estimate of$ 8.32 billion, while adjusted EPS was $1.39, surpassing the consensus of$ 1.36 [1][2] - The company experienced a year-over-year revenue increase of 2.5% and an organic growth of 4.1% [1] Revenue Breakdown - Cardiovascular segment revenue reached $3.04 billion, reflecting a 3.7% increase year-over-year and a 5% organic growth, with mid-single digit increases in Cardiac Rhythm & Heart Failure and Structural Heart & Aortic segments [3] - Neuroscience revenues amounted to$ 2.46 billion, up 4.4% as reported and 5.2% organically, driven by low-double-digit growth in Neuromodulation [4] - Medical Surgical revenue was $2.07 billion, showing a decrease of 1.9% as reported and 0.4% organically, with flat results in Surgical & Endoscopy [4] - Diabetes revenue increased to$ 694 million, marking an 8.4% rise as reported and 10.4% organically [5] Guidance and Market Reaction - Medtronic reaffirmed its fiscal year 2025 organic revenue growth guidance of 4.75%-5%, with adjusted EPS expectations of $5.44-$ 5.50, compared to the consensus of $5.45 [5] - Following the earnings report, MDT stock declined by 5.94% to$ 87.30 in premarket trading [6]